posted on Thursday, 18th February 2021
Not tagged.
Permalink
The CAPP2 clinical trial
led by Professor Sir John Burn, Newcastle University, has been
highlighted by the American Society of Clinical Oncology as an
Advance in Progress Against Cancer in their
16th Annual Report. The CAPP2 long term follow up paper was
published in the
Lancet in 2020.
It is a significant step for this cancer chemoprevention
research to be noted by the American Society of Clinical
Oncology.
CaPP3 is the follow up dose non-inferiority trial to
determine if this cancer chemoprevention can be observed with a
lower dose of aspirin.
posted on Wednesday, 10th February 2021
Not tagged.
Permalink
Business Beats Cancer Newcastle is an exciting new
initiative launching in 2021, bringing the North East business
community together to beat cancer.
To find our more and take part click
here